Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

J. Trigo; B.C. Cho; K. Park; N. Girard; S. Viteri; P. Garrido; M.G. Krebs; M. Thayu; R.E. Knoblauch; J. Xie; J.M. Bauml; R.W. Schnepp; A. Londhe; P. Mahadevia; N. Leighl

doi:10.1016/j.annonc.2022.02.029

YUHSpace

BROWSE

0 123

Cited 0 times in

Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

Authors: J. Trigo ; B.C. Cho ; K. Park ; N. Girard ; S. Viteri ; P. Garrido ; M.G. Krebs ; M. Thayu ; R.E. Knoblauch ; J. Xie ; J.M. Bauml ; R.W. Schnepp ; A. Londhe ; P. Mahadevia ; N. Leighl